Young v. Cerniak

467 N.E.2d 1045, 126 Ill. App. 3d 952, 81 Ill. Dec. 923, 1984 Ill. App. LEXIS 2225
CourtAppellate Court of Illinois
DecidedAugust 3, 1984
Docket83-702
StatusPublished
Cited by19 cases

This text of 467 N.E.2d 1045 (Young v. Cerniak) is published on Counsel Stack Legal Research, covering Appellate Court of Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Young v. Cerniak, 467 N.E.2d 1045, 126 Ill. App. 3d 952, 81 Ill. Dec. 923, 1984 Ill. App. LEXIS 2225 (Ill. Ct. App. 1984).

Opinion

JUSTICE SULLIVAN

delivered the opinion of the court:

This appeal is from a judgment for plaintiff in a wrongful death action alleging medical malpractice. Cerniak and Kassel (hereinafter defendants) 1 contend that (1) the trial court erred in (a) denying their motions for change of venue, and (b) entering judgment on inconsistent verdicts; (2) the jury was improperly instructed with regard to the appropriate standard of care; and (3) the verdicts against them are contrary to the manifest weight of the evidence.

It is undisputed that plaintiffs decedent, Robert Young (Young), was injured in a fall on January 23, 1975. For several days thereafter, he was treated by Dr. Duffy an orthopedic surgeon, who diagnosed a sprained wrist and a possible sprained or bruised right knee. However, Young complained of increasingly severe pain in his right calf throughout that period, and was eventually admitted to St. Joseph Hospital, where defendants and Dr. Wastalu, specialists in internal medicine, treated him for deep vein thrombophlebitis. On February 8, 1975, six days after treatment began, Young died as a result of a massive pulmonary embolism. The pertinent issues at trial were whether defendants deviated from the standard of care by failing to administer the proper amount of the anticoagulant Heparin, and by failing to detect symptoms of pulmonary emboli and provide proper treatment therefor, and whether their deviation from the standard of care was the proximate cause of Young’s death.

At trial, William Frescura, testifying for plaintiff as an adverse witness, stated that he was chief pharmacist at St. Joseph Hospital and a member of the hospital committee charged with developing the hospital formulary, a list of drugs which had been approved by the medical staff for treatment of patients in the hospital. One of the references used by the committee in generating that listing was the Physician’s Desk Reference, a compilation of package inserts provided by drug manufacturers which list usages of the drugs, pertinent warnings, and recommended dosages. Frescura further testified that the formulary set forth a procedure for the administration of Heparin, an anticoagulant which prolongs clotting time and prevents the formation of new clots as well as the extension and embolization of existing clots. According to the formulary, “Heparin effect is monitored by clotting time determinations,” and “[d]osage is that amount of Heparin which maintains the coagulation time at a level two to three times the patient’s normal coagulation time.” On cross-examination, Frescura agreed that a physician must exercise judgment in determining proper dosage, taking into account patient reaction as well as the manufacturer’s recommendations, and that, in the instant case, the physicians’ orders for 5,000 units of Heparin to be administered every four hours was within the recommended range of dosage.

Dr. Cerniak, testifying as an adverse witness, stated that he first examined Young on February 3, 1975, the day after his admission to the hospital, and that at that time he displayed the classic symptoms of deep vein thrombophlebitis, which is an inflammatory reaction in blood vessels leading to swelling and the formation of blood clots. Standard treatment for that condition is bed rest, elevation of the leg and application of heat, and administration of an anticoagulant to prevent the formation of further clots. According to Dr. Cerniak, that was the therapy provided in the instant case, and he ordered 5,000 units of the anticoagulant Heparin to be administered by intermittent intervenous injection every four hours, for a total dosage of 30,000 units in 24 hours, and a daily test of clotting time. Dr. Cerniak further stated that one possible complication of thrombophlebitis is pulmonary embolism, which occurs when a blood clot which has formed in the leg becomes dislodged, forming what is termed an embolus, and travels to the lungs. The autopsy on Young revealed that this was the cause of his death, and that report further indicated that there were numerous emboli in his lungs, ranging in age from more than one week old to the very recent, massive embolus which caused his death. However, it was impossible to determine when the clot which became the fatal embolism was formed.

Dr. Cerniak acknowledged that the dosage of Heparin remained the same throughout Young’s treatment; that the hospital laboratory form used to report the result of clotting-time tests stated that “therapeutic range should be 30 to 45 seconds,” but tests on Young showed clotting time ranging from 16 to 26 seconds, with a control time of 15 to 17 seconds; and that he was aware of the statement in the hospital formulary that “dosage is that amount of Heparin which maintains the coagulation time at a level two to three times the patient’s normal coagulation time.” He also agreed that the Physician’s Desk Reference recommends that the dosage be at this level, and that while that book states as guidelines an initial dose of 10,000 units followed by intermittent injections of 5,000 to 10,000 units every 4 to 6 hours, it also states that dosage must be adjusted for the individual patient based upon suitable laboratory tests.

Dr. Cerniak also testified that a number of physicians recognized as authorities in the field have advocated the use of tests to determine the anticoagulating effect of Heparin, and the maintenance of coagulation time at two to three times normal, and he acknowledged that this is the most popular approach. However, he noted that a number of other recognized authorities, including those at the Mayo Clinic where he received his training, advocated administration of a fixed dosage, as was given in the instant case, with periodic tests to insure that the dosage was not inordinately high, since a major risk in the use of Heparin is the occurrence of uncontrolled internal bleeding because of the anticoagulating effect of that drug. Many treatises by experts stated that there was no consensus among the medical community with regard to the need for laboratory monitoring of anticoagulant therapy. Dr. Cerniak admitted stating in a deposition that the therapeutic range for Heparin was that amount which achieved a clotting time approximately twice the patient’s normal clotting time. Nevertheless, he asserted that an equally acceptable method of treatment was to adjust dosage not only according to test results, but according to clinical observation. In the instant case, he maintained, all clinical signs indicated that Young’s condition was improving under the method chosen. His temperature did fluctuate slightly throughout treatment, but that could have been caused by the thrombophlebitis. Otherwise, Young indicated a lessening of pain in his right calf, the swelling had subsided, and his white blood cell count had decreased since admission to the hospital. Moreover, one of the classic symptoms of deep vein thrombosis, referred to as Homan’s sign (pain upon stretching the calf muscles), which was present when he first examined Young, had disappeared by the third or fourth day after admission. Finally, the nurses’ notes for that time period indicated that Young slept well, was not complaining of pain, and had a good appetite, all signs that he was responding to treatment.

Dr. Cerniak acknowledged that where acute pulmonary embolism is present, the proper dosage for Heparin is approximately 60,000 units per day; however, he stated that Young showed no symptoms of pulmonary embolism.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Perez v. Subsits
2020 IL App (1st) 192193-U (Appellate Court of Illinois, 2020)
Rodi v. Horstman
2015 IL App (1st) 142787 (Appellate Court of Illinois, 2015)
Spiegelman v. Victory Memorial Hospital
911 N.E.2d 1022 (Appellate Court of Illinois, 2009)
Southern Management Corp. v. Taha
836 A.2d 627 (Court of Appeals of Maryland, 2003)
Kramer v. Milner
639 N.E.2d 157 (Appellate Court of Illinois, 1994)
Ellington v. Bilsel
626 N.E.2d 386 (Appellate Court of Illinois, 1993)
Holston v. Sisters of the Third Order of St. Francis
618 N.E.2d 334 (Appellate Court of Illinois, 1993)
Mozer v. Kerth
586 N.E.2d 759 (Appellate Court of Illinois, 1992)
Colls v. City of Chicago
571 N.E.2d 951 (Appellate Court of Illinois, 1991)
Burke v. 12 Rothschild's Liquor Mart, Inc.
568 N.E.2d 80 (Appellate Court of Illinois, 1991)
Ramon by and Through Ramon v. Farr
770 P.2d 131 (Utah Supreme Court, 1989)
Thompson v. Carter
518 So. 2d 609 (Mississippi Supreme Court, 1987)
Piano v. Davison
510 N.E.2d 1066 (Appellate Court of Illinois, 1987)
Witherell v. Weimer
499 N.E.2d 46 (Appellate Court of Illinois, 1986)
Barenbrugge v. Rich
490 N.E.2d 1368 (Appellate Court of Illinois, 1986)
Walker v. Iowa Marine Repair Corp.
477 N.E.2d 1335 (Appellate Court of Illinois, 1985)

Cite This Page — Counsel Stack

Bluebook (online)
467 N.E.2d 1045, 126 Ill. App. 3d 952, 81 Ill. Dec. 923, 1984 Ill. App. LEXIS 2225, Counsel Stack Legal Research, https://law.counselstack.com/opinion/young-v-cerniak-illappct-1984.